2019 Mark Coventry 奖:氨甲环酸在翻修全膝关节置换术中给药方案的多中心随机临床试验:给药方案是否重要?
这项六中心随机临床试验将233例翻修全膝关节置换术随机分配至四种氨甲环酸给药方案之一,最终186例纳入分析。各组血红蛋白下降、计算失血量和输血率均无显著差异,等效性检验显示所有两两配对均统计学等效。作者建议外科医生在翻修全膝关节置换术中考虑使用最低有效剂量和最便宜的氨甲环酸方案。
要点
- 四种氨甲环酸方案在翻修全膝关节置换术中血液保护作用等效。
- 血红蛋白下降:单次静脉2.8 g/dl、双次静脉2.6 g/dl、静脉联合局部2.6 g/dl、口服2.9 g/dl,p=0.38。
- 作者建议翻修全膝关节置换术考虑使用最低有效剂量和最便宜的氨甲环酸方案。
核心结论
- 尽管翻修全膝关节置换术失血风险较高,但所测试的所有氨甲环酸方案均具有等效的血液保护作用。
- 作者建议外科医生在翻修全膝关节置换术中考虑使用最低有效剂量和最便宜的氨甲环酸方案。
研究设计与样本
- 多中心随机临床试验,来自六个中心,共233例翻修全膝关节置换术随机分配至四种氨甲环酸给药方案之一。
- 随机化基于翻修手术类型进行,以确保各组间分布均衡。
- 功效分析确定每组需要40例患者,以在α=0.05和把握度0.80下识别组间术后血红蛋白下降1 g/dl的差异。
- 符合方案分析涉及回归分析和两个单侧t检验用于等效性检验。
主要发现
- 共1例退出、5例未手术、16例筛选失败、25例未接受分配治疗,最终186例纳入分析。
- 血红蛋白下降在各治疗间无显著差异:单次静脉氨甲环酸2.8 g/dl、双次静脉氨甲环酸2.6 g/dl、静脉联合局部氨甲环酸2.6 g/dl、口服氨甲环酸2.9 g/dl,p=0.38。
- 计算失血量(p=0.65)和输血率(p=0.95)在各组间同样无显著差异。
- 假设血红蛋白变化1 g/dl差异为临床相关,等效性检验显示所有可能的两两配对均统计学等效。
关键数值与推荐
- 单次静脉氨甲环酸方案:皮肤切开前给予1 g静脉氨甲环酸。
- 双次静脉氨甲环酸方案:皮肤切开前和伤口闭合时各给予1 g静脉氨甲环酸。
- 静脉联合局部氨甲环酸方案:皮肤切开前给予1 g静脉氨甲环酸,术中给予1 g局部氨甲环酸。
- 口服氨甲环酸方案:术前两小时、术后六小时和术后第一天早晨给予三次1950 mg口服氨甲环酸。
临床怎么用
- 作者建议外科医生在翻修全膝关节置换术中考虑使用最低有效剂量和最便宜的氨甲环酸方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Tranexamic acid (TXA) is proven to reduce blood loss following total knee arthroplasty (TKA), but there are limited data on the impact of similar dosing regimens in revision TKA. The purpose of this multicentre randomized clinical trial was to determine the optimal regimen to maximize the blood-sparing properties of TXA in revision TKA. PATIENTS AND METHODS: From six-centres, 233 revision TKAs were randomized to one of four regimens: 1 g of intravenous (IV) TXA given prior to the skin incision, a double-dose regimen of 1 g IV TXA given both prior to skin incision and at time of wound closure, a combination of 1 g IV TXA given prior to skin incision and 1 g of intraoperative topical TXA, or three doses of 1950 mg oral TXA given two hours preoperatively, six hours postoperatively, and on the morning of postoperative day one. Randomization was performed based on the type of revision procedure to ensure equivalent distribution among groups. Power analysis determined that 40 patients per group were necessary to identify a 1 g/dl difference in the reduction of haemoglobin postoperatively between groups with an alpha of 0.05 and power of 0.80. Per-protocol analysis involved regression analysis and two one-sided t-tests for equivalence. RESULTS: In total, one patient withdrew, five did not undergo surgery, 16 were screening failures, and 25 did not receive the assigned treatment, leaving 186 patients for analysis. There was no significant difference in haemoglobin reduction among treatments (2.8 g/dl for single-dose IV TXA, 2.6 g/dl for double-dose IV TXA, 2.6 g/dl for combined IV/topical TXA, 2.9 g/dl for oral TXA; p = 0.38). Similarly, calculated blood loss (p = 0.65) and transfusion rates (p = 0.95) were not significantly different between groups. Equivalence testing assuming a 1 g/dl difference in haemoglobin change as clinically relevant showed that all possible pairings were statistically equivalent. CONCLUSION: Despite the higher risk of blood loss in revision TKA, all TXA regimens tested had equivalent blood-sparing properties. Surgeons should consider using the lowest effective dose and least costly TXA regimen in revision TKA. Cite this article: Bone Joint J 2019;101-B(Supple 7):10-16.
引用
- Fillingham YA, Darrith B, Calkins TE, et al. 2019 Mark Coventry Award: A multicentre randomized clinical trial of tranexamic acid in revision total knee arthroplasty: does the dosing regimen matter? Bone Joint J. 2019. PMID: 31256650. doi:10.1302/0301-620X.101B7.BJJ-2018-1451.R1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。